CORPORATE PRESENTATION

MAY 2017

DEPLOYING SYSTEM-BASED TECHNOLOGY FOR PERSONALIZED SPINAL CARE

5/16/171

2

SAFE HARBORThis document has been prepared by MEDICREA International (the “Company”) whose shares are admitted to trading on the Alternext market of Euronext in Paris, solely for information use as part of a roadshow presentation. By receiving this document and attending this meeting, you acknowledge having read the following restrictions.

This document is personal and strictly confidential and is not to be reproduced by any person, nor be distributed to any person other than to investors invited to such presentations and their colleagues. You must comply with all laws applicable to the possession of such information including laws on insider trading, the regulations or recommendations of the French Autorité des marchés financiers (the “AMF”). The distribution of this document in other jurisdictions may be restricted by law and persons, who come to hold it, should inform themselves about the existence of such restrictions and comply with them.

This document does not constitute an offer or invitation to purchase or subscribe for any shares and no part of it shall form the basis of, or be relied upon in connection with, any contract, commitment or investment decision in relation thereto. Any decision to purchase or subscribe for securities in connection with any future offer should be taken on the basis of information contained in a prospectus approved by the AMF or any other document of offer that would be made and issued by the Company in connection with this offer. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and comply with, any such restrictions. Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The information contained in this document (the “Information”) has not been independently verified and no representation or warranty, express or implied, is made as to the fairness, accuracy or completeness of the information or opinions contained herein. The Information is provided as at the date of this document and may change materially. The Company is under no obligation to keep current the information contained in this document and any opinions expressed in this document are subject to change without notice. Neither of the Company nor any of its affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss whatsoever arising from any use of this document or its contents, or otherwise arising in connection with this document. It is not the purpose of this presentation to provide, and you may not rely on this document as providing, a complete or comprehensive analysis of the Company’s financial or commercial position or prospects.

This document includes forward-looking statements that involve risks and uncertainties. The forward-looking statements are based on management’s current expectations or beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Given the uncertainty of the forward-looking statements, readers are advised that they do not constitute a guarantee, by the Company or anyone, to achieve the objectives and projects of the Company. Neither the Company nor any other person assumes liability for the accuracy and completeness of such forward-looking statements. The forward-looking statements contained in this document apply only to this document. Even if the Company’s financial condition, results of operations and cash flows and the development of the industry in which the Company operates are consistent with the forward-looking statements contained in this document, those results or developments may not be indicative of results or developments in future periods. The Company does not undertake any obligation to review or confirm analysts’ expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise after the date of this document.

5/16/17

3

THE FUTURE IS NOW

A NEW ERA IN SPINE SURGERY

5/16/17

“Personalized Spine Care” is the convergence of adaptive healthcare information technology and FDA-cleared outcome-centered spinal implants to scientifically deliver improved clinical results while providing system-wide cost reductions.

UNiD™ systems technology leverages proprietary, industry-leading data sets, predictive analytics and patient-specific implants and frees the company of antiquated product revenue streams and legacy manufacturing methods to refine global inventory requirements with in-house 3D printing

Medicrea believes each surgeon and patient is innately different. Thoughtful machine learning science must account for all of these variances. We provide each unique surgeon with personalized 21st Century Scientific Intelligence, enabling them to treat each patient individually with optimized, comprehensive, personalized procedural and implant solutions every day.

4

• HEADQUARTERED IN LYON, FRANCE AND NEW YORK CITY

• COMPREHENSIVE PERSONALIZED TECHNOLOGIES FOR COMPLEX SPINE MARKET

• FIRST TO MARKET PATIENT-SPECIFIC IMPLANTS FOR THE SPINE WITH UNID™ RODS

• COMPREHENSIVE 3D-PRINTED PATIENT-SPECIFIC PLATFORM IN-HOUSE

• CENTRALIZED HEADQUARTERS AND MANUFACTURING FACILITIES

• 2015 €27.8M. 2016 REVENUE OF €29.4M WITH 81% H1 GROSS MARGIN

• PUBLICLY TRADED ON ALTERNEXT: ALMED TICKER

• RAISED €20 MILLION WITH LEADING U.S. INVESTORS IN AUGUST LED BY ATHYRIUM CAPITAL

• RICK KIENZLE, FOUNDING MEMBER OF GLOBUS MEDICAL, APPOINTED CHIEF COMMERCIAL OFFICER

5/16/17

5

• INNOVATIVE SERVICE-ORIENTED APPROACH TO COMPLEX SPINE

• PATIENT SPECIFIC IMPLANTS DRIVE OPTIMAL PATIENT OUTCOMES

• DIFFERENTIATED UNiD TECHNOLOGY BENEFITS ALL KEY STAKEHOLDERS

• SIGNIFICANT GLOBAL MARKET OPPORTUNITY WITH LIMITED COMPETITION

• EXPERIENCED MANAGEMENT TEAM FOCUSED ON COMMERCIAL EXECUTION

• ATTRACTIVE FINANCIAL PROFILE

5/16/17

6

Denys SOURNACFounder, Chairman& CEO

Successful entrepreneur in the medical supply and

orthopaedics industry with over 30 years’ experience

creating, building and managing companies.

Pierre OLIVIERCEOMedicrea USA

Over 25 years’ experience in Marketing and Project

Management, mainly in the United States, particularly in

sales launches of new innovative products.

Fabrice KILFIGERChief Financial Officer

Over 25 years’ experience in finance,

including over 10 years heading the finance

divisions of listed companies.

Richard KIENZLEChief Commercial & BusinessDevelopment Officer

Co-founder of Globus Medical with over 25

years of Executive Sales Management

experience in the medical device industry.

David RYANVP Product Dev & Marketing

Biomechanical Engineer with more than 11 years’

experience in orthopedics. Former

R&D Director, Scient’x (Alphatec Spine).

5/16/17

IBD16%

CervicalFixation

15%

Bone Graft Extenders

17%Vertebral Compression Fracture

10%Spinal Electrical Stimulation

3%

Non Fusion4%

Thoracolumbar Fixation

35%

7

UNID TECHNOLOGIES U.S. MARKET OPPORTUNITY

NEARS $6B

1. 2015 Instrumented Thoracolumbar Procedures annually (409,100). 2013 Millennium Research Group, Inc., Table 87 “Thoracolumbar Fusions, by Indication.”

PATIENTSPECIFICUNiD 3D IBD & VBR

SYNTHETICBIOACTIVEBONE GRAFTEXTENDER

ANNUAL COMPLEX SPINE CASES1

116,000

ANNUAL DEGEN CASES1

221,000

AVG REVENUEPER DEGEN CASE

$11,200

AVG REVENUEPER COMPLEX CASE

$30,000

PATIENTSPECIFICDUAL-DIAMETER ROD

PATIENTSPECIFICROD

5/16/17

8

• Growing payer pressure on doctors to follow a measurable & systematic treatment plan with penalty charges applied for incurring revision surgery in the USA

• Increased legal liability concerns in achieving a successful outcomeand documenting the treatment plan in patient file

• Implant choices rely more now on hospital value-based strategy vs surgeon preference

• Achieving sagittal alignment for a patient post operation delivers the best clinical results

• The UNiD Lab / Surgeon relationship delivers far greater company / surgeon control with a new commercial sales paradigm that is much more cost effective than traditional sales rep structures.

• Medicrea’s Software system enables a huge reduction in intra op inventory creating a massive systemic efficiency and $ reduction (ex. 400-500 screws per case / reduced to 75).

5/16/17

9

Cone of Economy

1. Duval-Beaupere G, Schmidt C, Cosson PH (1992) A barycentremetric study of the sagittal shape of spine and pelvis. Ann Biomed Eng 20: 451–462

4 natural curves to spine in sagittal plane

PELVIC INCIDENCE IS UNIQUE TO

EACH PATIENT AND SET FOR

LIFE1

5/16/17

VARIABILITY IN NORMATIVE SPINE

105/16/17

INCREASING INCIDENCE OF IATROGENIC

SPINAL DEFORMITY3

OF AGING ADULTS PRESENT SPINAL DEFORMITY260%

1. Glassman SD, Bridwell K, Dimar JR, Horton W, Berven S and Schwab F, The Impact of Positive Sagittal Balance in Adult Spinal Deformity. Spine. 20052. Schwab F, Dubey A, Gamez L, et al. Adult scoliosis: prevalence, SF-36, and nutritional parameters in an elderly volunteer population. Spine 2005;30: 1082–53. Yousef A, Orndorff DO, Patty CA, et al. Current Status of Adult Spinal Deformity. Global Spine J 2013;3:51–62.

“You are either treating deformity, creating

deformity or ignoring deformity.” –SRS 2016

AGING SURGERY

SAGITTAL RE-ALIGNMENT & CLINICAL OUTCOMES ARE DIRECTLY LINKED1

11

Source: Iyer, Lenke, et al., 2016

1. Iyer S, Lenke LG, Nemani VM, Albert TJ, Sides BA, Metz LN, Cunningham ME, Kim HJ (2016) Variations in sagittal alignment parameters based on age: a prospective study of asymptomatic volunteers using full-body radiographs. Spine

Chain of correlation linking alignment of the lower extremitiesto the pelvis, spine, and occiput as well as global alignmentparameters.1

5/16/17

ALIGNMENT PARAMETERS

VARY BASED ON THE PATIENT’S

AGE AND COMPENSATORY

FACTORS.1

Source: Barrey et al., 2011

COMPENSATORY MECHANISMS FOR SAGITTAL

MALALIGNMENT

COMPLEX ALIGNMENT CONSIDERATIONS

125/16/17

7. Rod bending lab organized in 2012 included 8 spine surgeons and fellows from major US teaching institution

High Variability: Qualitative comparison between the real shape and the bending obtained by the attending and fellow groups.7

Post-op X-RayAttending Surgeons Fellows

ONE SIZE DOES NOT FIT ALL… HIGH VARIABILITY IN BENDING

131. Moal B, Schwab F, Ames CP, et al. Radiographic Outcomes of Adult Spinal Deformity Correction: A Critical Analysis of Variability and Failures Across

Deformity Patterns. Spine Deform. 2014.2. Rothenfluh DA, Mueller DA, et al. Pelvic incidence-lumbar lordosis mismatch predisposes to adjacent segment disease after lumbar spinal fusion. Eur Spine J

(2015) 24:1251-1258

CURRENT SHORTCOMINGS IN TREATMENT

LONG-TERMREPORTEDREVISION RATE437%

3. Smith JS, Shaffrey CI, Klineberg E, et al. Prospective multicenter assessment of risk factors for rod fracture following surgery for adult spinal deformity. J Neurosurg Spine 21:994–1003, 2014.4. Frymoyer JW, Matteri RE, Hanley EN, et al: Failed lumbar disc surgery requiring second operation. A long-term follow-up study. Spine 3:7-11, 19785. Jang J-S, Lee S-H, Min J-H, Kim SK, Han K-M, Maeng DH. Surgical treatment outcomeof failed back surgery syndrome due to sagittal imbalance. Spine (Phila. Pa. 1976). 2007

OF PATIENTS AREMALALIGNEDPOST-OP1

62%

OF MANUALLYBENT RODSFRACTURE39%

5/16/17

OF REVISIONS FAIL TO ACHIEVE ADEQUATE LUMBAR LORDISIS5

63%

22%FRACTURE-RATE WITH PSO3

INCREASED RISK OF ADJACENT LEVEL DISEASE2

14

MANUALCONTOURTime-consuming, intra-operative bending of straight rod to fit sagittal profile of patient using rudimentary instrument.

CURRENT STANDARD UNiD™ APPROACH

5/16/17

PATIENTSPECIFICData-driven, predictive Systems Technology with computer-assisted contouring of rods and machine-learning feedback loop.

2

3

4

5

6

7

1

pre-opservices

intra-opservices

post-opservices

16

BONE GRAFT SOLUTIONS

SPECIALIZED SYSTEMS FOR

COMPLEX SPINE

CUSTOMSAGITALLY

ALIGNEDRODS

CUSTOMINTERBODY

DEVICES

5/16/17

TWENTYFOUR / SEVENSUPPORTNo matter where you are in the world, experienced biomechanical engineers work with you to simplify your life, utilizing empirical, precise and accurate surgical planning

medicrea.com leading personalized spine

ONE-TO-ONE ENGINEERING COLLABORATION§ DIGITAL ANATOMICAL MEASUREMENTS

§ SURGICAL PLAN SIMULATION

§ PER-OPERATIVE CASE MEMO

§ PATIENT-SPECIFIC IMPLANT

§ STATISTICAL ANALYSIS

§ INTEGRATED REPORTING

DEDICATED EXPERTS

17

24/7 SUPPORT

5/16/17

A New Relationship & Cohesion Paradigm Between The Company & Surgeon

18

PATIENT MEDICREA3RD PARTY PAYERHOSPITALSURGEON

IMPROVED OUTCOMES

TIME SAVINGS

REDUCED COST

OPTIMIZED INVENTORY

POSITIVE DIFFERENTIATION

PATIENT SELECTION

CONSTITUENTS

BEN

EFIT

S

INTRA-OPCONFIRMATION

5/16/17

10. McCarthy IM, Hostin RA, Ames CP, et al. Total hospital costs of surgical treatment for adult spinal deformity: an extended follow-upstudy. Spine J. 2014

SUBSTANTIAL LONG-TERM SAVINGS FOR ALL STAKE-HOLDERS

Increase in the overall average costs of adult spinal deformity surgery for patients

requiring revisions and reoperations10

70%

Costs associatedwith hospital readmission10

$80,000

REDUCED RISK OF REVISION AND TIME-SAVING TECHNOLOGY

19

13. Range of $22/min to $133/min, across 100 hospitals in the U.S. Shippert RD. A Study of Time-Dependent Operating Room Fees.The American Journal of Cosmetic Surgery, 2005 Vol. 22, No. 1.14. Survey of U.S. Spinal Surgeons on Rod Bending Time. Medicrea Survey Results. 2015.

ASSOCIATEDTIME & COST REDUCTION

BENEFITSUS spinal surgeons, on national

average, spend 15 minutes manually bending spinal rods in the O.R.13

$100 / minute national average cost in the O.R.14

Potential savings by procedure by minimizing manual rod

bending in the O.R.

$1,500

5/16/17

1 MORE SURGEONS USING UNiD PLATFORM AND RODS

2 CONVERTED SURGEONS INCREASING UNiD UTILIZATION

3 MORE REVENUE PER PROCEDURE

UNID RODs UNID IBDsPROPRIETARY

BIO-ACTIVE BGE

PEDICLE SCREWS

Least commoditized

Low conversion sensitivity

Most commoditized

Higher conversion sensitivity

ENGAGE FULLY CONVERT

5/16/1720

21

RAPID MONTHLY INCREASE IN UNiD™ PATIENT-SPECIFIC SURGERIES SINCE RELEASE

FDACLEARED

USED WITH MEDICREA FIXATION

74%

TOTAL US UNiD CASE REVENUE

(15% PREMIUM ONPATIENT-SPECIFIC)

$13.0M

5/16/17

PATIENTS TREATED AS OF 30 APR ‘17

H22014

H12015

H22015

H12016

H22016

April'17

1355GLOBAL

693EUROPE

662U.S.A.

225/16/17

• 2016 revenue of €29.4M

• High gross margin in the 80 % range

• Significant capex spendings in 2016 & 2015 to increase in-source of production and manufacturing efficiency

• EBITDA positive since 2010

• 160+ Headcount

• Transformative € 20M fundraising in August 2016, including € 15M from Athyrium Capital Management in US and € 5M from multiple US investors & Executive team

AT A GLANCE

23

MANUFACTURING• IN-HOUSE TITANIUM 3D PRINTING PATIENT-SPECIFIC IBD & VBR

• U.S. UNiD ROD MANUFACTURING FOR DEGENERATIVE DEFORMITY MARKET

• BRING STERILIZATION CAPABILITIES IN-HOUSE

• SIGNIFICANT COST REDUCTION AND INCREASED EFFICIENCY IN INVENTORYMANAGEMENT VIA UNiD PLATFORM PREDICTIVE TECHNOLOGIES

SALES AND MARKETING• RICK KIENZLE APPOINTED TO LEAD COMMERCIALIZATION EFFORTS • DRIVE REVENUE WITH INTEGRATED PRODUCT SOLUTIONS THROUGH UNiD

TECHNOLOGY ADOPTION• BUILD BODY OF EVIDENCE FOR PATIENT-SPECIFIC UNiD ROD

• INCREASE PRESENCE WITH KOLS IN STRATEGIC HOSPITALS AND CENTERS

• INCREASE AWARENESS WITH UNiD WARRANTY PROGRAM

• EXPAND ONLINE MARKETING CAMPAIGN AIMED AT US PATIENTS

5/16/17

24

Q1 ‘17

NEW TECHNOLOGY DEVELOPMENT

• PREDICTIVE, MACHINE LEARNING THRU BIG DATA COMPILATION AND MINING

• COMPLETE UNiD MIS DEVELOPMENT• FDA FILE SUBMISSION FOR PATIENT-SPECIFIC 3D-PRINTED

• UNiD LAB ONLINE INTERFACE • UNiD 3D BIPLANAR ROD DEVELOPMENT, MARKET RELEASE

• FDA CLEARANCE OF PATIENT-SPECIFIC 3D-PRINTED INTERBODY & VERTEBRAL BODY REPLACEMENT DEVICES

Q2 ‘17

Q3 ‘17

5/16/17

25

• INNOVATIVE SERVICE-ORIENTED APPROACH TO COMPLEX SPINE

• PATIENT SPECIFIC IMPLANTS DRIVE OPTIMAL PATIENT OUTCOMES

• DIFFERENTIATED UNiD TECHNOLOGY BENEFITS ALL KEY STAKEHOLDERS

• SIGNIFICANT GLOBAL MARKET OPPORTUNITY WITH LIMITED COMPETITION

• EXPERIENCED MANAGEMENT TEAM FOCUSED ON COMMERCIAL EXECUTION

• ATTRACTIVE FINANCIAL PROFILE

5/16/17

26

UNiD : A New Era In Patient Carehttps://www.youtube.com/watch?v=jRwrDg_bca4

UNiD in the NEWS : New Frontiershttps://www.youtube.com/watch?v=OaOccVBrJpk

FDA Approved : Medicrea Announces UNiD Cervical Rodhttps://www.youtube.com/watch?v=Z55zvgtqvVs

Patient-facing websitewww.personalizedspinalimplants.com

Medicrea US Website Newsroomhttp://www.medicrea.com/usa/newsroom-usa/

VIDEOS

PATIENT-FACING

PRESS RELEASES

5/16/17

QUOTES

“The patient-specific rod is very much ahead of its time. When we finish the operation, we’ve left them with the best possible appearance for the rest of their lives. The curve is not going to worsen and there is less likelihood of them having pain.”

- Dr. Andrew King, Children’s Hospital New Orleans

“We now realize how important it is to provide a specific alignment of the spine that is unique to each patient. If we do not achieve the optimal alignment during surgery, then we are too-often revising that patient later. UNiD™ is using precision technology and analysis to solve this clinical issue for patients as well as providing an invaluable support service and feedback loop for surgeons.”

- Dr. Evalina Burger, University of Colorado Hospital

“Understanding and restoring sagittal alignment is key towards providing better patient outcomes and preventing the need for reoperations, a major factor in rising health care costs. By providing rod customization, UNiD™ allows surgeons to precisely execute their preoperative plan and frees them from the antiquated technique of freehand bending, ensuring individual patients receive the most accurate and effective treatment. Having a more precise, personalized rod ready before even stepping foot in the operating room is a game-changer for spine surgery.”

– Dr Schwab, HSS, New York

275/16/17

RICK KIENZLE FULL BIO

Mr Richard Kienzle, also known as Rick, has been Chief Commercial & Business Development Officer at Medicrea since August 2016. Mr Kienzle is a successful spine executive with a deep network in the World-Wide Spine Markets. He is a Founder and served as the Executive Vice President Global Sales and Marketing of Globus Medical, Inc. (Ticker symbol GMED) from 2003 to 2011. His responsibilities included all global sales, marketing, training and commercial functions of Globus including the development of an exclusive national distribution network. During Mr Kienzle’s tenure, Globus was widely noted as the fastest growing company in orthopedic history. GMED closed a $110M private placement with Goldman Sachs and Clarus Ventures in 2007 and an IPO with Goldman and BOA in 2012. Prior to Globus, he served for 5 years as Area Vice President; Synthes Spine where he was responsible for all sales and marketing functions at this top-performing enterprise with over $90M in annual revenue (30% compounded growth rate). Mr Kienzle’s experience also includes 8 prior years with United States Surgical Corp working side-by-side in the OR with surgeons of all surgical specialties, followed by a series of promotions and culminating as the National Business Director. He has additional experience in the banking field working for The Equitable Financial Companies and Mellon Bank. He has been a Director at Medicrea since August 2016. Mr Kienzle received his Bachelor of Arts from Denison University. Mission: to oversee the commercial expansion of Medicrea’s patient-specific UNiD technology and personalized treatment modalities.

Chief Commercial & Business Development Officer, Director

SPINOPELVIC PARAMETERS PRE-OPERATIVE CASE PLAN POST-OPERATIVE

Pelvic Tilt (PT,˚) 25 10 12

Pelvic Incidence (PI,˚) 35 35 35

Sacral Slope (SS,˚) 10 25 23

Lumbar Lordosis (LL,˚) 21 43 43

PI-LL (˚) 14 -9 -9

Thoracic Kyphosis (TK,˚) 42 42 42

T1 Pelvic Angle (TPA,˚) 21 6 6

Sagittal Vertical Alignment (SVA,mm) 38* 17 -15.2

Detail Information

Surgery Date 2 / 2 / 2015

Levels T10-Pelvis

Type of Rod Standard

Rod Material CoCr

Rod Diameter 6.0

28

ADULT DEFORMITY CASE

5/16/17